Commencement date: 26 April 2021 (Limited quota)
Service target:
Patients of Hong Kong public hospitals managed by Hospital Authority requiring to use ADAMTS13 as a differential diagnosis tool to identify Atypical Hemolytic Uremic Syndrome (AHUS)
Applicantion criteria:
1. Valid HKID card holder
2. Patient of public hospitals of Hospital Authority of Hong Kong
3. With ADAMTS13 diagnostic test referral letter from public hospitals of Hospital Authority of Hong Kong within program period from 26 April 2021 to 31 March 2022
4. Never received Eculizumab treatment
Upon application approval and verification of required documents, eligible patients can get one ADAMTS 13 test at designated local private test centre.
Please contact SafeMed Dispensary at 2979 0380 for enquiries about the program details.